Abstract

The muscular dystrophy X-linked mouse (mdx) is the most commonly used preclinical model for Duchenne muscular dystrophy. Although disease progression in the mouse does not perfectly model the human disease, it shares many pathological features. Early characterizations of the model reported severe pathology through early adulthood followed by disease stabilization. As a result, research in the mdx mouse has largely focused on early adulthood. The overarching goal of this study is to improve the understanding of the mdx mouse model by tracking pathological features of the disease throughout life. We performed a thorough characterization of myofiber pathology in mdx mice from 2 weeks to 2 years of age. We report that individual mdx muscle fibers undergo progressive hypertrophy that continues through the lifespan. Despite massive hypertrophy on the myofiber level, we report no hypertrophy on the muscle level. These seemingly contradictory findings are explained by previously underappreciated myofiber loss in mdx mice. We conclude that due to myofiber loss, in combination with the progressive nature of other pathological features, aged mdx muscle tissue provides reliable benchmarks for disease progression that may be valuable in testing the efficacy of therapeutics for Duchenne muscular dystrophy.

Highlights

  • The muscular dystrophy X-linked mouse is the most commonly used preclinical model for Duchenne muscular dystrophy

  • Mdx myofibers do not seem to be susceptible to atrophy associated with sarcopenia. These results indicate that the myofiber hypertrophy seen in mdx is progressive and does not follow the pattern seen in Duchenne muscular dystrophy (DMD)

  • By tracking pathological features through the lifespan of the mdx mouse, we identified that myofiber hypertrophy does not mimic the pattern of muscle growth and atrophy seen in ­DMD48

Read more

Summary

Introduction

The muscular dystrophy X-linked mouse (mdx) is the most commonly used preclinical model for Duchenne muscular dystrophy. As in DMD, mdx mice lack dystrophin p­ rotein[4] Initial characterizations dismissed this strain as a viable experimental model for human muscular dystrophy, reporting that the mice undergo a severe bout of muscle damage and repair between 3 and 12 weeks of age, followed by a functional and anatomical r­ ecovery[5,6,7]. Mdx mice do not progressively lose muscle strength and the ability to ­ambulate[8] They have been reported to have a more robust regenerative response than DMD patients leading to effective replacement of damaged muscle tissue rather than deposition of fibrotic and adipose ­tissue[6,9,10]. Central nuclei, muscle hypertrophy, myofiber branching, and shortened lifespans are features of both the human disease and the mouse ­model[3,14,15,16,17]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call